Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go

Table 1

Prognostic subgroups and associated risk genetic factors in CLL at diagnosis.

Category	Associated; genetic factors	Therapeutic strategies
Very high risk	del(17p)*/TP53 mutation; and/or; BIRC3 mutation	p53-independent drugs,; BTK inhibitors,; allogeneic stem cell transplantation
High risk	del(11q)*/ATM mutation; and/or; NOTCH1 mutation; and/or; SF3B1 mutation	FCR
Intermediate risk	Trisomy 12; Normal karyotype and FISH	Not recommended
Low risk	Isolated del(13q)*	Not recommended

FCR: fludarabine, cyclophosphamide, and rituximab; *higher percentages of deleted nuclei have bad impact on prognosis (Tam et al., 2009 [11]; Hernández et al., 2009 [12]; van Dyke et al., 2010 [13]; Dal Bo et al., 2011 [14]; Marasca et al., 2013 [15]; Puiggros et al., 2013 [21]).